Education
About Us
Working with TipRanks
Follow Us
Puretech Health Plc (PRTC)
:PRTC
PRTC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$13.30 - $25.82
Previous CloseN/A
Volume2.03K
Average Volume (3M)3.83K
Market Cap
$435.12M
Enterprise Value$130.14M
Total Cash (Recent Filing)$367.31M
Total Debt (Recent Filing)$22.36M
Price to Earnings (P/E)8.7
Beta0.74
Next Earnings
Aug 27, 2025EPS Estimate
-2.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.60
Shares Outstanding24,131,632
10 Day Avg. Volume1,389
30 Day Avg. Volume3,832
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.30
Enterprise Value/Revenue30.16
Enterprise Value/Gross Profit30.16
Enterprise Value/Ebitda3.48
Forecast
1Y Price Target
$46.00Price Target Upside151.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Business StrategyPRTC operates a hybrid business model, allowing them to retain optionality to develop programs in-house or to deploy assets into spinoff companies in which PRTC retains ownership.
Clinical TrialsPRTC announced positive results from the Ph 2b ELEVATE study of LYT-100, which is seen as supportive of a role in the IPF landscape as an improvement to standard of care anti-fibrotics.
Drug EfficacyLYT-100 demonstrates meaningfully improved efficacy with roughly comparable-to-improved safety compared to standard pirfenidone.
Bears Say
Stock LiquidityInvestor interest in PRTC stock is limited by the expectation that promising assets will get spun out plus the low liquidity for the ADRs.
Stock ValuationPRTC stock continues to trade only modestly above cash levels as investors struggle with low liquidity for the ADRs and valuing the 'hub' of the 'hub-and-spoke' R&D model.
PureTech Health News
PRTC FAQ
What was Puretech Health Plc’s price range in the past 12 months?
Puretech Health Plc lowest stock price was $13.30 and its highest was $25.82 in the past 12 months.
What is Puretech Health Plc’s market cap?
Puretech Health Plc’s market cap is $435.12M.
When is Puretech Health Plc’s upcoming earnings report date?
Puretech Health Plc’s upcoming earnings report date is Aug 27, 2025 which is in 19 days.
How were Puretech Health Plc’s earnings last quarter?
Puretech Health Plc released its earnings results on Apr 30, 2025. The company reported $3.6 earnings per share for the quarter, beating the consensus estimate of -$2.83 by $6.43.
Is Puretech Health Plc overvalued?
According to Wall Street analysts Puretech Health Plc’s price is currently Undervalued.
Does Puretech Health Plc pay dividends?
Puretech Health Plc does not currently pay dividends.
What is Puretech Health Plc’s EPS estimate?
Puretech Health Plc’s EPS estimate is -2.04.
How many shares outstanding does Puretech Health Plc have?
Puretech Health Plc has 24,131,632 shares outstanding.
What happened to Puretech Health Plc’s price movement after its last earnings report?
Puretech Health Plc reported an EPS of $3.6 in its last earnings report, beating expectations of -$2.83. Following the earnings report the stock price went down -1.371%.
Which hedge fund is a major shareholder of Puretech Health Plc?
Currently, no hedge funds are holding shares in PRTC
PureTech Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$46.00 (151.64% Upside)
$46.00 (151.64% Upside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.66%
12-Months-Change
Fundamentals
Return on Equity
11.96%
Trailing 12-Months
Asset Growth
-13.16%
Trailing 12-Months
Company Description
Puretech Health Plc
PureTech Health (PRTC) is a biopharmaceutical company focused on discovering, developing, and commercializing highly differentiated medicines for devastating diseases. The company operates in the healthcare and biotechnology sectors, primarily targeting areas such as immunology, inflammation, and central nervous system disorders. PureTech Health is known for its unique approach, which involves leveraging insights from diverse scientific disciplines to address significant healthcare needs.
PRTC Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant achievements such as successful clinical trial results and FDA approval, alongside challenges like market valuation disconnect and funding requirements for future trials.View all PRTC earnings summariesPRTC Stock 12 Month Forecast
Average Price Target
$46.00
▲(151.64% Upside)
Technical Analysis
EyePoint Pharmaceuticals
―
Zevra Therapeutics
―
Autolus Therapeutics
―
Stoke Therapeutics
―
AbSci
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
1.45% Other Institutional Investors
98.55% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---